Oxford Biomedica PLC Dr Frank Mathias to join as new CEO on 27 March (3622Q)

TIDMOXB

RNS Number : 3622Q

Oxford Biomedica PLC

20 February 2023

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

- Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica

- Stuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director

Oxford, UK - 20 February 2023: Oxford, UK - Oxford Biomedica (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer (CEO) and Board member on Monday, 27th March 2023. His appointment was previously announced on 22nd November 2022.

Dr Frank Mathias joins Oxford Biomedica from Rentschler Biopharma SE ("Rentschler") where he has been CEO since 2016. He successfully transformed Rentschler into a leading global, full-service CDMO and transformed the financials of the business including a three-fold increase in revenue, while also improving efficiencies and profitability at an even faster rate.

Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: "We are extremely excited about the imminent arrival of Frank as our new CEO. Frank brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica and I feel, with Frank's new leadership, we are extremely well-positioned to deliver the growth and full potential of the company given our leading technology. As a viral vector leader, Oxford Biomedica is poised to build its position as a world-class, innovation-led CDMO delivering life-changing therapies to patients."

Dr Frank Mathias, incoming Chief Executive Officer, said: "I look forward to joining Oxford Biomedica and leading the Company in its mission to deliver innovative services to biopharma customers, enabling them to discover and deliver therapies that transform patients' lives. Oxford Biomedica has a clear vision for the future, and I believe it has great potential to become the leader in the viral vector CDMO market. I firmly believe in the Company's strategy for growth and am excited to start working towards our goal to deliver products to patients as quickly as possible."

In addition, Oxford Biomedica announce s two changes to its Board , both of which will also take effect on 27 (th) March 2023. Stuart Henderson will become Vice Chair, a newly created position which replaces the previously combined role of Deputy Chair and Senior Independent Director, the position Stuart has filled since June 2020. Professor Dame Kay Davies will assume the role of Senior Independent Director, following her appointment as a Non-Executive Director in March 2021.

-Ends-

Enquiries :

Oxford Biomedica plc:

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E: ir@oxb.com

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

   Mary-Jane Elliott / Matthew Cole            / Matthew Neal

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUMCPUPWGBB

(END) Dow Jones Newswires

February 20, 2023 02:00 ET (07:00 GMT)

Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025